Xuelei Chu

Xuelei Chu

Auto-generated profile, based on publicly available information

Xuelei Chu

Department of Oncology Guang'anmen Hospital, China Academy of Chinese Medical Sciences Beijing China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
FXFeiyu Xie
Feiyu Xie
MWMina Wang
Mina Wang
YSyixin Su
yixin Su
KXKunmin Xiao
Kunmin Xiao
XCXuelei Chu
Xuelei Chu
SZShijie Zhu
Shijie Zhu
Background. Lung metastasis of malignant tumor signifies worse prognosis and immensely deteriorates patients’ life quality. Spatholobi Caulis (SC) has been reported to reduce lung metastasis, but the mechanism remains elusive. Methods. The active components and corresponding targets of SC were obtained from the Traditional Chinese Medicine Database and Analysis Platform (TCMSP) database and the SwissTargetPrediction database. The disease targets were acquired from DisGeNET and GeneCards databases. Venn map was composed to figure out intersection targets by using R. The PPI network was constructed through STRING and Cytoscape, and MCODE plug-in was used to sift hub targets. Gene Ontology (GO)-Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was carried out by utilizing clusterProfiler package (R3.6.1) with adjusted value <0.05. Network of SC-active components-intersection targets-KEGG pathway was accomplished with Cytoscape. Molecular docking between hub targets and active components was performed, analyzed, and visualized by AutoDockTools, AutoDock Vina, PLIP Web tool, and PYMOL. Results. 24 active components and 123 corresponding targets were screened, and the number of disease targets and intersection targets was 1074 and 47, respectively. RELA, JUN, MAPK1, MAPK14, STAT3, IL-4, ESR1, and TP53 were the 8 hub targets. GO analysis and KEGG analysis elucidated that SC could ameliorate lung metastasis mainly by intervening oxidative stress, AGE-RAGE signaling pathway, and microRNAs in cancer. All 8 hub targets were proven to combine successfully with active components of SC. Conclusion. Inflammation is the core factor that integrates all these targets, biological process, and signaling pathways, which indicates that SC prevents or reduces lung metastasis mainly by dispelling inflammation.

1 January 2024 in Integrative Cancer Therapies
Verified
Journal Article
Open access
XCXuelei Chu
Xuelei Chu
FXFeiyu Xie
Feiyu Xie
CHChengzhi Hou
Chengzhi Hou
XZXin Zhang
Xin Zhang
SWSijia Wang
Sijia Wang
SZShijie Zhu
Shijie Zhu
Background: Siwu Decoction (SWD) is a well-known classical TCM formula that has been shown to be effective as a basis for preventing and reducing liver metastases (LM). However, the active ingredients and potential molecular mechanisms remain unclear. Objective: This study aimed to systematically analyze the active ingredients and potential molecular mechanisms of SWD on LM and validate mechanisms involved. Materials and methods: The active ingredients in SWD were extracted by UHPLC-MS/MS in a latest study. Protox II was retrieved to obtain toxicological parameters to detect safety. Swiss Target Prediction database was exploited to harvest SWD targets. Five databases, Gene Cards, DisGeNET, Drugbank, OMIM, and TTD, were employed to filter pathogenic targets of LM. STRING database was utilized to construct the protein–protein interaction network for therapeutic targets, followed by Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. GEPIA database and the Human Protein Atlas were taken to observe the expression of core genes and proteins. ImmuCellAI algorithm was applied to analyze the immune microenvironment and survival relevant to core genes. Molecular docking was performed to verify the affinity of SWD effective ingredients to core targets. In vivo experiments were carried out to validate the anti-LM efficacy of SWD and verify the pivotal mechanisms of action. Results: Eighteen main bioactive phytochemicals identified were all non-hepatotoxic. PPI network acquired 118 therapeutic targets, of which VEGFA, CASP3, STAT3, etc. were identified as core targets. KEGG analysis revealed that HIF-1 pathway and others were critical. After tandem targets and pathways, HIF-1/VEGF was regarded as the greatest potential pathway. VEGFA and HIF-1 were expressed differently in various stages of cancer and normal tissues. There was a negative regulation of immunoreactive cells by VEGFA, which was influential for prognosis. Molecular docking confirmed the tight binding to VEGFA. This study revealed the exact effect of SWD against LM, and identified significant inhibition the expression of HIF-1α, VEGF, and CD31 in the liver microenvironment. Conclusion: This study clarified the active ingredients of SWD, the therapeutic targets of LM and potential molecular mechanisms. SWD may protect against LM through suppressing HIF-1/VEGF pathway.

9 July 2021
Verified
Book Chapter
Closed access
PDF file
XCXuelei Chu
Xuelei Chu
WHWeiguo Huo
Weiguo Huo
QFQicheng Fan
Qicheng Fan
RLRuoxin Liu
Ruoxin Liu
For CO2 trapped in the ultramafic xenoliths in the Cenozoic alkaline basalts of eastern China, C and O isotopic ratios vary respectively in ranges of -9.9 to -35.7%c and +25.5 to +0.7%0. It is notable that there seem to be a good positive correlation between the 813C and 8180 values of CO2 extracted at the same temperature for Minqing and Wangqing samples.


23 September 2026 in Thoracic Cancer
Verified
Journal Article
Open access
YSYuting Sun
Yuting Sun
XCXuelei Chu
Xuelei Chu
XWXinmiao Wang
Xinmiao Wang
WLWeina Li
Weina Li
XZXiaoyu Zhu
Xiaoyu Zhu
JLJie Li
Jie Li
Although immunotherapy has completely transformed the treatment landscape of nonsmall cell lung cancer (NSCLC), its wide application is still limited by the heterogeneity of patient responses, primary and acquired resistance, as well as the management challenges of immune‐related adverse events (irAEs). To achieve precise individualized immunotherapy, this review systematically summarizes the multidimensional biomarker profiles that can predict the efficacy, resistance, and safety of immunotherapy. Beyond the single PD‐L1 expression, the efficacy prediction system has expanded to integrate multimodal information such as dynamic tumor microenvironment, tumor genomic characteristics, systemic inflammation/immune status, and radiomics. At the same time, studies have revealed that immune‐suppressive microenvironments and specific genetic variations are key mechanisms mediating treatment resistance. Moreover, clinical characteristics, blood markers, and imaging findings provide a basis for predicting the risk of irAEs. Looking to the future, the core to overcoming current bottlenecks lies in constructing dynamic and integrated prediction models. By integrating multiomics data, longitudinal liquid biopsies, and artificial intelligence algorithms, an intelligent decision‐making system is expected to be developed to achieve real‐time monitoring of treatment response, early identification of resistance mechanisms, and proactive management of toxicity risks, ultimately optimizing the clinical practice of NSCLC immunotherapy and advancing it towards higher‐order precision medicine.